Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets.

Flaherty KT.

Clin Exp Metastasis. 2012 Oct;29(7):841-6. doi: 10.1007/s10585-012-9488-y. Epub 2012 Jun 3.

PMID:
22661223
2.

Targeted therapies for cutaneous melanoma.

Kee D, McArthur G.

Hematol Oncol Clin North Am. 2014 Jun;28(3):491-505. doi: 10.1016/j.hoc.2014.02.003. Epub 2014 Apr 3. Review.

PMID:
24880943
3.

[Targeted molecular therapies (except immunotherapy)].

Roux J, Pages C, Lebbé C.

Bull Cancer. 2014 Dec;101 Suppl 2:S25-36. doi: 10.1684/bdc.2014.2053. Review. French.

PMID:
25776764
4.

[Translational research and diagnostics of melanoma].

Rüschoff J, Kleinschmidt M, Middel P.

Pathologe. 2012 Nov;33 Suppl 2:291-5. doi: 10.1007/s00292-012-1661-1. Review. German.

PMID:
22968732
5.

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.

Spagnolo F, Ghiorzo P, Queirolo P.

Oncotarget. 2014 Nov 15;5(21):10206-21. Review.

6.

The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.

Akabane H, Sullivan RJ.

Am J Clin Dermatol. 2016 Feb;17(1):1-10. doi: 10.1007/s40257-015-0159-z. Review.

PMID:
26518880
7.

Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.

Johnson GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, Graves LM.

Clin Cancer Res. 2014 May 15;20(10):2516-22. doi: 10.1158/1078-0432.CCR-13-1081. Epub 2014 Mar 24.

8.

Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.

Johnson AS, Crandall H, Dahlman K, Kelley MC.

J Am Coll Surg. 2015 Apr;220(4):581-93.e1. doi: 10.1016/j.jamcollsurg.2014.12.057. Epub 2015 Jan 30.

PMID:
25797743
9.

[Melanoma: from molecular studies to the treatment breakthrough].

Imianitov EN.

Arkh Patol. 2013 Sep-Oct;75(5):63-72. Review. Russian.

PMID:
24341237
10.

Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.

Jang S, Atkins MB.

Clin Pharmacol Ther. 2014 Jan;95(1):24-31. doi: 10.1038/clpt.2013.197. Epub 2013 Sep 30. Review.

PMID:
24080641
11.

Targeted therapy in melanoma.

Kudchadkar RR, Smalley KS, Glass LF, Trimble JS, Sondak VK.

Clin Dermatol. 2013 Mar-Apr;31(2):200-8. doi: 10.1016/j.clindermatol.2012.08.013. Review.

PMID:
23438383
12.

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS.

Cancer Discov. 2014 Jan;4(1):80-93. doi: 10.1158/2159-8290.CD-13-0642. Epub 2013 Nov 21.

13.

Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.

Seremet T, Lienard D, Suppa M, Trepant AL, Rorive S, Woff E, Cuylits N, Jansen Y, Schreuer M, Del Marmol V, Neyns B.

Melanoma Res. 2015 Apr;25(2):180-3. doi: 10.1097/CMR.0000000000000145.

PMID:
25643238
14.

Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?

Sloot S, Fedorenko IV, Smalley KS, Gibney GT.

Expert Opin Pharmacother. 2014 Apr;15(5):589-92. doi: 10.1517/14656566.2014.881471. Epub 2014 Jan 24.

PMID:
24456413
15.

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, McKenna A, Cibulskis K, Farlow D, Zimmer L, Hillen U, Gutzmer R, Goldinger SM, Ugurel S, Gogas HJ, Egberts F, Berking C, Trefzer U, Loquai C, Weide B, Hassel JC, Gabriel SB, Carter SL, Getz G, Garraway LA, Schadendorf D; Dermatologic Cooperative Oncology Group of Germany (DeCOG)..

Cancer Discov. 2014 Jan;4(1):94-109. doi: 10.1158/2159-8290.CD-13-0617. Epub 2013 Nov 21.

16.

Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.

Patel SP, Lazar AJ, Papadopoulos NE, Liu P, Infante JR, Glass MR, Vaughn CS, LoRusso PM, Cohen RB, Davies MA, Kim KB.

Cancer. 2013 Feb 15;119(4):799-805. doi: 10.1002/cncr.27790. Epub 2012 Sep 12.

17.

Overcoming metastatic melanoma with BRAF inhibitors.

Hong S, Hong S, Han SB.

Arch Pharm Res. 2011 May;34(5):699-701. doi: 10.1007/s12272-011-0521-5. Review.

PMID:
21656352
18.

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, Cibulskis K, Kryukov G, Hodis E, Lawrence DP, Fisher S, Getz G, Gabriel SB, Carter SL, Flaherty KT, Wargo JA, Garraway LA.

Cancer Discov. 2014 Jan;4(1):61-8. doi: 10.1158/2159-8290.CD-13-0631. Epub 2013 Nov 21.

19.

Dabrafenib therapy for advanced melanoma.

Trinh VA, Davis JE, Anderson JE, Kim KB.

Ann Pharmacother. 2014 Apr;48(4):519-29. doi: 10.1177/1060028013513009. Epub 2013 Nov 20. Review.

PMID:
24259661
20.

Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".

Jarkowski A 3rd, Norris L, Trinh VA.

Ann Pharmacother. 2014 Nov;48(11):1456-68. doi: 10.1177/1060028014544165. Epub 2014 Jul 23. Review.

PMID:
25056920

Supplemental Content

Support Center